News
DSRLF
86.00
NaN%
--
Barclays Keeps Their Sell Rating on DiaSorin S.p.A. (0GZX)
TipRanks · 3d ago
DiaSorin downgraded to Hold from Buy at Kepler Cheuvreux
TipRanks · 09/02 09:00
UBS Sticks to Its Sell Rating for DiaSorin S.p.A. (0GZX)
TipRanks · 08/24 08:25
Europe's Other Story: 5 Reasons The Continent's Equities Are Worth A Closer Look
Seeking Alpha · 07/17 04:10
DiaSorin speculated to have rebuffed takeover offer from US suitor - report
Seeking Alpha · 07/10 15:53
DiaSorin downgraded to Underperform from Neutral at BNP Paribas
TipRanks · 07/07 09:05
Kepler Capital Reaffirms Their Buy Rating on DiaSorin S.p.A. (0GZX)
TipRanks · 06/27 01:36
DiaSorin initiated with a Buy at Kepler Cheuvreux
TipRanks · 06/25 08:40
DiaSorin S.p.A. (0GZX) Gets a Buy from RBC Capital
TipRanks · 06/25 01:46
DiaSorin downgraded to Sell from Hold at Deutsche Bank
TipRanks · 06/17 08:30
Twist Bio favored at Piper despite wait-and-see approach for tools stocks
Seeking Alpha · 06/11 15:24
DiaSorin jumps amid takeover speculation
Seeking Alpha · 06/04 15:02
DiaSorin S.p.A. (0GZX) Initiated with a Buy at Banco Santander
TipRanks · 06/03 06:55
DiaSorin S.p.A. reports Q2 results
Seeking Alpha · 05/08 20:32
DiaSorin price target lowered to EUR 62 from EUR 65 at Deutsche Bank
TipRanks · 04/29 15:55
DiaSorin downgraded to Neutral from Buy at UBS
TipRanks · 04/09 08:45
DiaSorin S.p.A. (0GZX) was downgraded to a Hold Rating at UBS
TipRanks · 04/09 08:29
DiaSorin price target lowered to EUR 65 from EUR 74 at Deutsche Bank
TipRanks · 03/27 18:56
DiaSorin price target lowered to EUR 60 from EUR 65 at Morgan Stanley
TipRanks · 03/23 16:41
DiaSorin S.p.A. reports FY results
Seeking Alpha · 03/20 17:42
More
Webull provides a variety of real-time DSRLF stock news. You can receive the latest news about Diasorin through multiple platforms. This information may help you make smarter investment decisions.
About DSRLF
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.